PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 301-325 of 369

  • PI3Kδ-IN-8
    Cat. No.
    A79827

    PI3Kδ-IN-8

    PI3Kδ-IN-8 is a selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ) with an IC50 value of 3.3 nM. It demonstrates a pronounced selectivity for PI3Kδ compared to PI3Kα, PI3Kβ, and PI3Kγ, exhibiting IC50 values of 377.2 nM, 241.6 nM, and 17.9 nM, respectively. This compound has shown significant anti-tumor activity, making it a valuable tool for research in cancer therapeutics and cellular signaling pathways involving PI3Kδ.

    5 mg
    $795.00
    All 1 sizes
  • GSK251
    Cat. No.
    A79828

    GSK251

    GSK251 is a potent and selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) isoform, exhibiting a novel binding mechanism. It demonstrates significant biological activity by effectively impeding PI3Kδ signaling pathways, which are crucial in various immune responses and hematological malignancies. GSK251 is utilized in research applications focused on understanding the role of PI3Kδ in cancer therapy and immune modulation.

    1 mg
    $135.00
    5 mg
    $340.00
    All 6 sizes
  • CHF-6523
    Cat. No.
    A79829

    CHF-6523

    CHF-6523 is a selective inhibitor of PI3Kδ, which plays a crucial role in cellular signaling pathways. This compound exhibits potent biological activity in modulating immune responses and has been employed in research focused on chronic obstructive pulmonary disease (COPD). Its ability to inhibit PI3Kδ makes it a valuable tool for investigating therapeutic strategies targeting immune and inflammatory processes associated with COPD.

    Out of stock

    All 3 sizes
  • PI3K-IN-9
    Cat. No.
    A79830

    PI3K-IN-9

    PI3K-IN-9 is a potent and selective inhibitor of PI3Kδ, demonstrating an IC50 of 8.9 nM. This compound effectively modulates PI3K signaling pathways, making it a valuable tool in research focused on cancer and immune responses. It is applicable in studies evaluating the role of PI3Kδ in various diseases, including hematological malignancies and inflammatory disorders.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kγ inhibitor 4
    Cat. No.
    A79831

    PI3Kγ inhibitor 4

    PI3Kγ Inhibitor 4 is a selective, orally bioavailable inhibitor targeting the phosphoinositide 3-kinase gamma (PI3Kγ) enzyme, demonstrating an IC50 of 40 nM. It exhibits notable selectivity ratios of approximately 7-fold, 43-fold, and 18-fold against the α, β, and δ isoforms, respectively. This compound is valuable for studying airway inflammation and may contribute to understanding associated pathological conditions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K-IN-63
    Cat. No.
    A79832

    PI3K-IN-63

    PI3K-IN-63 is a potent inhibitor of PI3Kα, exhibiting a Ki of 0.35 nM against human targets. This compound effectively inhibits the phosphorylation of AKT at the S473 site in cellular assays, demonstrating its capacity to interfere with critical signaling pathways. PI3K-IN-63 has shown efficacy in reducing the viability of non-small cell lung cancer cell lines harboring PIK3CA mutations, making it a valuable tool for research related to this type of cancer.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes
  • Amdizalisib
    Cat. No.
    A79833

    Amdizalisib

    Synonyms: HMPL-689

    Amdizalisib is a selective inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, which plays a crucial role in various cellular functions, including metabolism, growth, and survival. This compound demonstrates significant anti-proliferative effects in cancer cells and modulates immune responses, making it a valuable reagent for research applications focused on inflammatory diseases, autoimmune disorders, and oncology. Amdizalisib serves as an important tool for advancing the understanding of PI3K-related mechanisms in both disease states and therapeutic development.

    5 mg
    $795.00
    All 1 sizes
  • AM-8508
    Cat. No.
    A79834

    AM-8508

    AM-8508 is a potent PI3Kδ inhibitor, demonstrating an IC50 of 0.016 μM. It selectively targets PI3Kδ, effectively blocking AKT phosphorylation associated with B cell receptor signaling. Research has shown that AM-8508 suppresses the production of antigen-specific IgG and IgM in immunized rats, highlighting its potential applications in the study of inflammatory diseases. This compound serves as a valuable tool for investigating the role of PI3Kδ in immune responses.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • AM-1430
    Cat. No.
    A79835

    AM-1430

    AM-1430 is a highly selective and orally active inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) enzyme, with an IC50 value of 4.6 nM. This compound demonstrates significantly higher IC50 values for PI3Kα, PI3Kβ, and PI3Kγ, at 14.18 μM, 2.2 μM, and 3.22 μM, respectively. AM-1430 effectively inhibits B cell proliferation and shows strong in vivo activity, particularly in models of pAKT inhibition and hemoglobin (KLH) immune response. This reagent is suitable for research focused on inflammation and autoimmune diseases.

    Out of stock

    All 3 sizes
  • PI3Kα-IN-12
    Cat. No.
    A79836

    PI3Kα-IN-12

    PI3Kα-IN-12 is a highly selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) with an IC50 of 1.2 nM. It demonstrates significant antiproliferative activity against HCT-116 and U87-MG cell lines, with IC50 values of 0.83 μM and 1.25 μM, respectively. In vivo, PI3Kα-IN-12 induces tumor regression in a U87-MG xenograft model at a dosage of 40 mg/kg administered intraperitoneally, making it a valuable tool for research on cancer therapy targeting the PI3K signaling pathway.

    Out of stock

    All 3 sizes
  • PI3Kα-IN-19
    Cat. No.
    A79837

    PI3Kα-IN-19

    PI3Kα-IN-19 is a selective inhibitor of PI3Kα, targeting the p110α catalytic subunit. This compound demonstrates significant biological activity in inhibiting the PI3Kα pathway, which is frequently dysregulated in various cancers. PI3Kα-IN-19 is valuable for researching cancer biology and evaluating therapeutic strategies that involve modulation of the PI3Kα signaling pathway.

    25 mg
    $1,655.00
    50 mg
    $2,115.00
    All 3 sizes
  • FAP-PI3KI1
    Cat. No.
    A79838

    FAP-PI3KI1

    FAP-PI3KI1 is a fibroblast-activated protein (FAP) inhibitor that selectively targets the phosphoinositide 3-kinase (PI3K) pathway in FAP-expressing human cells. This compound effectively inhibits collagen synthesis and reduces collagen deposition, making it a valuable tool for research in idiopathic pulmonary fibrosis (IPF) and related fibrotic conditions. Its targeted action facilitates investigating the role of the PI3K signaling pathway in fibrosis and offers potential insights into therapeutic strategies for IPF.

    Out of stock

    All 3 sizes
  • PI3K-IN-27
    Cat. No.
    A79839

    PI3K-IN-27

    PI3K-IN-27 is a targeted inhibitor of phosphoinositide 3-kinase (PI3K), a critical component in cellular signaling pathways that govern processes such as cell growth, differentiation, migration, and apoptosis. This compound exhibits potent inhibitory activity against PI3K, making it valuable for investigating hyper-proliferative diseases, including cancer and inflammation, as well as immune and autoimmune disorders. Its role in modulating PI3K activity underscores its potential utility in preclinical research settings.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • (S)-Zovegalisib
    Cat. No.
    A79840

    (S)-Zovegalisib

    Synonyms: (S)-RLY-2608

    (S)-Zovegalisib, the S-enantiomer of RLY-2608, is a novel allosteric inhibitor of PI3Kα, selectively targeting mutant forms of the enzyme. It demonstrates potent anti-tumor activity, making it a valuable compound for cancer research. This reagent is particularly useful in studies focused on the role of PI3Kα mutations in tumorigenesis and therapeutic responses.

    5 mg
    $330.00
    10 mg
    $545.00
    All 5 sizes
  • PI3K-IN-28
    Cat. No.
    A79841

    PI3K-IN-28

    PI3K-IN-28 is a selective inhibitor of phosphoinositide 3-kinase (PI3K), showcasing significant potency in inhibiting its activity. With half-maximal inhibitory concentration (IC50) values of 5.8, 2.3, and 7.9 µM, PI3K-IN-28 demonstrates reduced toxicity in MCF-10a cell lines and a selectivity index (SI) of 39, highlighting its potential for anticancer applications. This compound serves as a promising lead for further development of targeted therapeutics in cancer research.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Dezapelisib
    Cat. No.
    A79842

    Dezapelisib

    Synonyms: INCB040093

    Dezapelisib is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ) that demonstrates significant antitumor activity. This compound is primarily utilized in research focused on relapsed or refractory B-cell lymphomas, making it a valuable tool for understanding the therapeutic potential of targeted PI3Kδ inhibition in hematological malignancies. Its mechanism of action contributes to the modulation of cell proliferation and survival pathways, offering insights into cancer treatment strategies.

    25 mg
    $1,530.00
    50 mg
    $1,950.00
    All 3 sizes
  • PI3K-IN-38
    Cat. No.
    A79843

    PI3K-IN-38

    PI3K-IN-38 is an orally active inhibitor of phosphoinositide 3-kinase (PI3K), with an IC50 of 0.541 µM for PI3K-α. This compound demonstrates significant anticancer and anti-inflammatory properties, effectively inhibiting tumor growth in vivo. Its selective modulation of the PI3K pathway makes it a valuable tool for research into cancer therapies and inflammatory diseases.

    1 mg
    $65.00
    5 mg
    $150.00
    All 6 sizes
  • NVP-CLR457
    Cat. No.
    A79844

    NVP-CLR457

    NVP-CLR457 is a potent pan-class I PI3K inhibitor that exhibits oral bioavailability and a favorable pharmacokinetic/pharmacodynamic relationship. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. NVP-CLR457 is suitable for studies focused on the roles of PI3K signaling in various cancer types and therapeutic resistance mechanisms.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • PI3Kα-IN-22
    Cat. No.
    A79845

    PI3Kα-IN-22

    PI3Kα-IN-22 is a potent and selective inhibitor of the PI3KαH1047R mutant, demonstrating an IC50 of 1 nM in the pAKT T47D AlphaLISA assay. This orally active compound has shown the ability to induce tumor regressions in the HCC1954 mouse model, making it a valuable tool for studying PI3Kα-related pathways in cancer research and therapeutic development. Its specificity and efficacy support its use in investigations aimed at targeting PI3Kα-driven malignancies.

    Out of stock

    All 3 sizes
  • TGX-155
    Cat. No.
    A79846

    TGX-155

    Synonyms: AZ12649385

    TGX-155 is a selective inhibitor of PI3Kβ, a key enzyme involved in the phosphoinositide 3-kinase signaling pathway. This compound exhibits significant antithrombotic activity, making it a potential therapeutic agent for the treatment of thrombotic disorders. Its application in research may enhance the understanding of PI3Kβ-related mechanisms in cardiovascular biology and drug development.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K-IN-51
    Cat. No.
    A79847

    PI3K-IN-51

    PI3K-IN-51 is a potent inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, exhibiting IC50 values below 500 nM for the p120γ and p110δ/p85α isoforms. This compound is crucial for investigating the role of PI3K in cellular processes such as growth, proliferation, and survival. It has applications in cancer research and other fields where PI3K signaling plays a significant role in disease progression.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PF-376304
    Cat. No.
    A79848

    PF-376304

    PF-376304 is an orally active, non-specific class I phosphoinositide 3-kinase (PI3K) inhibitor, exhibiting an IC50 of 0.197 μM against PI3Kγ. This compound is shown to induce dose-dependent metabolic disorders related to glucose and lipid metabolism in animal models, with rapid lethality observed at elevated doses. Additionally, metabolic abnormalities induced at lower doses demonstrate self-reversibility. PF-376304 is valuable for research into metabolic and inflammatory diseases, providing insights into PI3K involvement in these pathological conditions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • (R)-IHMT-PI3Kδ-372
    Cat. No.
    A79850

    (R)-IHMT-PI3Kδ-372

    (R)-IHMT-PI3Kδ-372 is a selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) pathway, exhibiting an IC50 of 19 nM. This compound is primarily utilized in research related to chronic obstructive pulmonary disease (COPD), where modulation of the PI3Kδ signaling pathway may provide therapeutic insights. Its potency and specificity make it a valuable tool for investigating PI3Kδ's role in inflammatory and immune responses.

    1 mg
    $25.00
    5 mg
    $55.00
    All 6 sizes
  • FD2056
    Cat. No.
    A79852

    FD2056

    FD2056 is a potent, orally active inhibitor of the phosphoinositide 3-kinase (PI3K) family, with specific inhibition of PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, exhibiting IC50 values of 0.30, 0.80, 1.10, and 0.42 nM, respectively. This compound also targets cyclin-dependent kinases, inhibiting CDK2-CyclinA2 and CDK4-CyclinD3 with IC50 values of 115.95 nM and 2782.15 nM. FD2056 demonstrates significant antiproliferative effects in breast cancer cell lines, with IC50 values of 1.06 μM for MDA-MB-231, 0.04 μM for MDA-MB-468, and 1.40 μM for MCF-7 cells. Additionally, FD2056 promotes apoptosis in cancer cells and effectively inhibits tumor growth.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kδ-IN-3
    Cat. No.
    A79853

    PI3Kδ-IN-3

    PI3Kδ-IN-3 is a selective inhibitor of the PI3Kδ isoform, exhibiting an IC50 of 9 nM. This compound effectively inhibits B cell function, making it a valuable tool for studying immune responses and related disorders. With favorable pharmacokinetic properties, PI3Kδ-IN-3 is suitable for in vitro and in vivo research applications in the field of immunology and cancer therapeutics.

    1 mg
    $70.00
    5 mg
    $160.00
    All 7 sizes

Items 301-325 of 369

Added to your cart

View Cart Checkout

    Loading...